Evidence map›Paper›PMID 26539227›Full record

ReviewEvidence-based complementary and alternative medicine : eCAM2015

Resistance to Antibiotics and Antifungal Medicinal Products: Can Complementary and Alternative Medicine Help Solve the Problem in Common Infection Diseases? The Introduction of a Dutch Research Consortium.

Esther T Kok, Miek C Jong, Barbara Gravendeel, Willem B Van Leeuwen, Erik W Baars

Open access · hybridAbstract readReview
In one paragraph

Review in Evidence-based complementary and alternative medicine : eCAM, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
6.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Esther T KokUniversity of Applied Sciences, 2333 CK Leiden, Netherlands ; Centre for Academic Primary Care, School of Social and Community Medicine, University of Bristol, Bristol BS8 2PS, UK.
Miek C JongDepartment of Healthcare and Nutrition, Louis Bolk Institute, 2972 LA Driebergen, Netherlands ; Department of Health Sciences, Mid Sweden University, 871 31 Sundsvall, Sweden ; National Information and Knowledge Centre on Integrative Medicine (NIKIM), Amsterdam, Netherlands.
Barbara GravendeelUniversity of Applied Sciences, 2333 CK Leiden, Netherlands ; Naturalis Biodiversity Center, 2333 CR Leiden, Netherlands.
Willem B Van LeeuwenUniversity of Applied Sciences, 2333 CK Leiden, Netherlands.
Erik W BaarsUniversity of Applied Sciences, 2333 CK Leiden, Netherlands ; Department of Healthcare and Nutrition, Louis Bolk Institute, 2972 LA Driebergen, Netherlands.
Louis Bolk Instituut · NLNaturalis Biodiversity Center · NLUniversity of Applied Sciences Leiden · NLUniversity of Bristol · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increase of antibiotic resistance worldwide, rising numbers of deaths and costs associated with this, and the fact that hardly any new antimicrobial drugs have been developed during the last decade have increased the interest in Complementary and Alternative Medicine (CAM) therapeutic interventions, if proven safe and effective. Observational studies on clinical CAM practices demonstrate positive effects of treatment of infections with CAM therapies (clinical effects, patient satisfaction) in combination with small percentages of antibiotics prescription. However, Cochrane reviews and other studies demonstrate that in most instances the quality of clinical trials on CAM treatment of infections is currently too low to provide sufficient evidence. Therefore a Dutch consortium on (in vitro and clinical) scientific research on CAM and antibiotic resistance has been formed. The aim and objective of the consortium is to establish an enduring partnership and to develop expertise to further develop and investigate safe and effective CAM treatments for infectious diseases of humans (and animals). A first ongoing project on the development of safe and effective biobased CAM antimycotics in women with (recurrent) vaginal candidiasis infection is introduced.

Identifiers

PMID26539227
PMCPMC4619906
OpenAlexW2138779602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.